Indeed, molecular docking studies have revealed that cucurbitacins show a significant binding towards the crystal structure of RAF and MEK, comparable to that of the standard B-RAF and MEK inhibitors, imparting cucurbitacins the ability to inhibit the ERK activation in melanoma cells (33). Here, MAP2K7 is linked to melanoma.